SAM
ESPR

Silverback Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Silverback Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Hold
0
– – – 76
2024
Q1 		– Sell
-100,000
Closed -$603K – 78
2023
Q4 		$603K Hold
100,000
– – 0.08% 75
2023
Q3 		$198K Hold
100,000
– – 0.03% 78
2023
Q2 		$280K Hold
100,000
– – 0.04% 78
2023
Q1 		$321K Buy
+100,000
New +$516K 0.04% 82

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Silverback Asset Management's ESPR Position: Q3 2024 in Review

Silverback Asset Management held its Esperion Therapeutics (ESPR) position steady in Q3 2024 at 0 shares worth $168K. The position accounts for 0.02% of the portfolio, ranked #76.

Silverback Asset Management first reported a position in ESPR in Q1 2023 and has held it in 4 quarters since. The position peaked at $603K in Q4 2023. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Silverback Asset Management held 0 shares of Esperion Therapeutics worth $168K as of Q3 2024.
  • Silverback Asset Management left its Esperion Therapeutics share count unchanged in Q3 2024.
  • Esperion Therapeutics made up 0.02% of Silverback Asset Management's portfolio in Q3 2024, its #76 holding.
  • Silverback Asset Management first reported a position in Esperion Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Silverback Asset Management's Esperion Therapeutics position peaked at $603K in Q4 2023.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Silverback Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.